Search results
Results from the WOW.Com Content Network
The drug or other substance has a potential for abuse less than the drugs or other substances in schedules I and II. The drug or other substance has a currently [2] accepted medical use in treatment in the United States. Abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence.
The Federal Motor Carrier Safety Administration (FMCSA) is an agency in the United States Department of Transportation that regulates the trucking industry in the United States. The primary mission of the FMCSA is to reduce crashes, injuries, and fatalities involving large trucks and buses.
Logo: SAMHSA's National Registry of Evidence-based Programs and Practices (NREPP), www.nrepp.samhsa.gov. In the behavioral health field, there is an ongoing need for researchers, developers, evaluators, and practitioners to share information about what works to improve outcomes among individuals coping with, or at risk for, mental disorders and substance abuse.
The Drug Addiction Treatment Act of 2000 (DATA 2000), Title XXXV, Section 3502 of the Children's Health Act, permits physicians who meet certain qualifications to treat opioid addiction with Schedule III, IV, and V narcotic medications that have been specifically approved by the Food and Drug Administration for that indication.
A Drug Recognition Expert (DRE) is a law enforcement officer trained in a scientifically validated method to identify people whose driving is impaired by drugs other than, or in addition to, alcohol. All DREs follow the same 12 step procedure called a Drug Influence Evaluation (DIE), to purportedly determine which category of drugs is causing ...
The Substance Abuse and Mental Health Services Administration (SAMHSA; pronounced / ˈ s æ m s ə /) is a branch of the U.S. Department of Health and Human Services.SAMHSA is charged with improving the quality and availability of treatment and rehabilitative services in order to reduce illness, death, disability, and the cost to society resulting from substance abuse and mental illnesses.
The Drug Enforcement Administration was established on July 1, 1973, [4] by Reorganization Plan No. 2 of 1973, signed by President Richard Nixon on July 28. [5] It proposed the creation of a single federal agency to enforce the federal drug laws as well as consolidate and coordinate the government's drug control activities.
At that time, responsibility for the DAWN and NHSDA programs were transferred to the Substance Abuse and Mental Health Services Administration (SAMHSA). NIDA is organized into divisions and offices, each of which is involved with programs of drug abuse research. Nora Volkow, MD, has been the director of NIDA since 2003. [3] According to NIH: